The US Food and Drug Administration (FDA) has approved Switzerland-based Roche's Vilsardelli for the treatment of advanced breast cancer in combination with Novartis' Afinitor, the Wall Street Journal reports. Roche expects annual sales of the new drug to exceed 3 billion Swiss francs ($3.57 billion) at its peak, potentially making it the company's best-selling product.